Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience
Mariangela Ciccarese, Giammarco Surico(Ospedale Vito Fazzi), Luciana Petrucelli(Ospedale Vito Fazzi), Luca Moscetti(Ospedale di Belcolle), Maria Morritti(Casa Sollievo della Sofferenza), Elisabetta De Matteis(Unknown), Antonio Cusmai(Radiation Oncology Institute), Nicla La Verde(ASST Fatebenefratelli Sacco), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Alessandra Fabi(Agostino Gemelli University Polyclinic), Evaristo Maiello(Casa Sollievo della Sofferenza), Marianna Giampaglia(Ospedale San Carlo), Giuseppe Cairo(Ospedale Vito Fazzi), Antonio Febbraro(Fatebenefratelli Hospital), Laura Isabella Lupo(Ospedale Vito Fazzi), Francesco Giotta(Istituto Tumori Bari), Gennaro Palmiotti(Radiation Oncology Institute), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Vincenzo Emanuele Chiurì, Vito Lorusso, R. Forcignanò(Ospedale Vito Fazzi), S. Romito(Ospedali Riuniti di Foggia), Claudio Scavelli(Gallipoli Medical Research Foundation), Agnese Latorre(Istituto Tumori Bari), Guido Giordano(University of Foggia)
Cited by 12
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer
|JNCI Journal of the National Cancer Institute|2001|275